The binding of lead compounds and drugs to human serum albumin (HSA) is a ubiquitous problem in drug discovery since it modulates the availability of the leads and drugs to their intended target, which is linked to biological efficacy. In our continuing efforts to identify small molecule αVβ3 and αVβ5 dual antagonists, we recently reported indoles 2–4 as potent and selective αVβ3/αVβ5 antagonists with good oral bioavailability profile. In spite of ...